DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Mifamurtide

Mifamurtide

  • Mepact, INN-Mifamurtide

    Mepact, INN-Mifamurtide

  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

  • WO 2013/138665 Al 19 September 2013 (19.09.2013) P O P C T

    WO 2013/138665 Al 19 September 2013 (19.09.2013) P O P C T

  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

  • Kosei Et Al.Pdf

    Kosei Et Al.Pdf

  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

  • Analysis of Biological Treatments in Patients with Multiple Sclerosis in Estonia

    Analysis of Biological Treatments in Patients with Multiple Sclerosis in Estonia

  • Mifamurtide Therapy

    Mifamurtide Therapy

  • Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer

    Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer

  • Role of Tumor-Associated Macrophages in Sarcomas

    Role of Tumor-Associated Macrophages in Sarcomas

  • WHO Drug Information Vol

    WHO Drug Information Vol

  • NICE TECHNOLOGY APPRAISAL MEDICINES REPORT St George’S Healthcare NHS Trust Compliance Indicator Key for Medicine-Related NICE Technology Appraisals

    NICE TECHNOLOGY APPRAISAL MEDICINES REPORT St George’S Healthcare NHS Trust Compliance Indicator Key for Medicine-Related NICE Technology Appraisals

  • Metastatic Osteosarcoma Who Received Treatment with Mifamurtide in Two Institutions in Co

    Metastatic Osteosarcoma Who Received Treatment with Mifamurtide in Two Institutions in Co

  • Lists of Medicinal Products for Rare Diseases in Europe*

    Lists of Medicinal Products for Rare Diseases in Europe*

  • Regulatory Information 12152014

    Regulatory Information 12152014

  • Mifamurtidever1.1

    Mifamurtidever1.1

  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

  • United States Patent ( 10 ) Patent No.: US 10,478,439 B2 Honigberg Et Al

    United States Patent ( 10 ) Patent No.: US 10,478,439 B2 Honigberg Et Al

Top View
  • MEPACT® Prescribing Information
  • (INN) for Biological and Biotechnological Substances
  • Access to Cancer Medicines in Europe: an Analysis of Existing Challenges and Countries’ Responses
  • Estonian Statistics on Medicines 2014
  • Advances on the Formulation of Proteins Using Nanotechnologies
  • Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
  • List Item Minutes of the PRAC Meeting 6-9 October 2014
  • Mifamurtide and TAM-Like Macrophages: Effect on Proliferation, Migration and Differentiation of Osteosarcoma Cells
  • NICE Tas RFL Formulary Sept 2016
  • Future Directions in the Treatment of Osteosarcoma
  • Microencapsulated Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceutical Agents
  • Vaccine Efficacy Against Primary and Metastatic Cancer with in Vitro-­Generated CD103+ Conventional Dendritic Cells
  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances
  • Who Drug Information
  • Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
  • Nanotechnology As a Platform for the Development of Injectable Parenteral Formulations: a Comprehensive Review of the Know-Hows and State of the Art
  • Pharmaabkommen A1 E
  • ABSTRACT BOOK 18Th Congress of the EAHP, 13-15 March 2013, Paris, France March 2013


© 2024 Docslib.org    Feedback